GLP-1 agonists are great, but they have a major downside: they can cause muscle loss along with fat loss. Scientists in Sweden have created an experimental pill that gives the benefits of GLP-1 without this problem. This new pill focuses on muscles instead of appetite. Early results from clinical trials, published in Cell, show that the treatment is safe and well-tolerated in both healthy people and those with type 2 diabetes.
This drug is a new kind of beta-2 agonist. It seems to boost muscle mass and cut fat without the heart issues seen in earlier drugs of this type. The research team thinks this treatment could be a valuable option for people with obesity and diabetes, whether used alone or with GLP-1. Atrogi AB is leading its development, while other companies are also looking into similar methods to target myostatin or activin to help maintain muscle mass.
